Maykin Ho, Ph.D.

Maykin Ho brings more than 30 years of experience in the healthcare and finance industries to the Parexel Board. She is a former Partner at The Goldman Sachs Group, where she was a top-ranked biotechnology research analyst, Co-Head of U.S. Healthcare for Global Investment Research and Advisory Director for Global Investment Banking. Prior to Goldman Sachs, Maykin held managerial positions at DuPont and DuPont-Merck Pharmaceuticals. Maykin served on Parexel’s Board of Directors when the company was publicly listed, and during Pamplona’s ownership.

She serves on the boards of Agios Pharmaceuticals, BioMarin, Kyntra, Neumora and Pelage Pharmaceuticals. Maykin is also a venture partner at Aulis Capital and member of the Biotech Panel for the Hong Kong Stock Exchange. Previously, she was a member of the Board of Directors at Grail, Inc. Maykin holds a Ph.D. in microbiology and immunology and a Bachelor of Science from the State University of New York, Downstate Medical Center.

She was a postdoctoral fellow at Harvard Medical School and is also a graduate of the Advanced Management Program at Duke University’s Fuqua School of Business.